Keren Z Landman1, Kathrine R Tan2, Paul M Arguin3. 1. U.S. Centers for Disease Control and Prevention, Center for Global Health/Malaria Branch, 1600 Clifton Rd NE, MS A06, Atlanta, GA 30333, USA. Electronic address: klandman@gmail.com. 2. U.S. Centers for Disease Control and Prevention, Center for Global Health/Malaria Branch, 1600 Clifton Rd NE, MS A06, Atlanta, GA 30333, USA. Electronic address: ktan@cdc.gov. 3. U.S. Centers for Disease Control and Prevention, Center for Global Health/Malaria Branch, 1600 Clifton Rd NE, MS A06, Atlanta, GA 30333, USA. Electronic address: parguin@cdc.gov.
Abstract
BACKGROUND: Although malaria can be prevented with prophylaxis, it is diagnosed in over 100 Africa-region Peace Corps Volunteers annually. This suggests that prophylaxis non-adherence is a problem in these non-immune travelers. METHODS: We investigated Volunteers' knowledge, attitudes, and practices regarding prophylaxis using an internet-based survey during August 19-September 30, 2013. Adherence was defined as taking doxycycline or atovaquone-proguanil daily, or taking mefloquine doses no more than 8 days apart. RESULTS: The survey was sent to 3248 Volunteers. Of 781 whose responses were analyzed, 514 (73%) reported adherence to prophylaxis. The most common reasons for non-adherence were forgetting (n = 530, 90%); fear of long-term adverse effects (LTAEs; n = 316, 54%); and experiencing adverse events that Volunteers attributed to prophylaxis (n = 297, 51%). Two hundred fourteen (27%) Volunteers reported not worrying about malaria. On multivariate analysis controlling for sex and experiencing adverse events Volunteers attributed to prophylaxis, the factor most strongly associated with non-adherence was being prescribed mefloquine (OR 5.4, 95% confidence interval 3.2-9.0). CONCLUSIONS: We found moderate adherence and a prevailing fear of LTAEs among Volunteers. Strategies to improve prophylaxis adherence may include medication reminders, increasing education about prophylaxis safety and malaria risk, and promoting prompt management of prophylaxis side effects. Published by Elsevier Ltd.
BACKGROUND: Although malaria can be prevented with prophylaxis, it is diagnosed in over 100 Africa-region Peace Corps Volunteers annually. This suggests that prophylaxis non-adherence is a problem in these non-immune travelers. METHODS: We investigated Volunteers' knowledge, attitudes, and practices regarding prophylaxis using an internet-based survey during August 19-September 30, 2013. Adherence was defined as taking doxycycline or atovaquone-proguanil daily, or taking mefloquine doses no more than 8 days apart. RESULTS: The survey was sent to 3248 Volunteers. Of 781 whose responses were analyzed, 514 (73%) reported adherence to prophylaxis. The most common reasons for non-adherence were forgetting (n = 530, 90%); fear of long-term adverse effects (LTAEs; n = 316, 54%); and experiencing adverse events that Volunteers attributed to prophylaxis (n = 297, 51%). Two hundred fourteen (27%) Volunteers reported not worrying about malaria. On multivariate analysis controlling for sex and experiencing adverse events Volunteers attributed to prophylaxis, the factor most strongly associated with non-adherence was being prescribed mefloquine (OR 5.4, 95% confidence interval 3.2-9.0). CONCLUSIONS: We found moderate adherence and a prevailing fear of LTAEs among Volunteers. Strategies to improve prophylaxis adherence may include medication reminders, increasing education about prophylaxis safety and malaria risk, and promoting prompt management of prophylaxis side effects. Published by Elsevier Ltd.
Entities:
Keywords:
Malaria chemoprophylaxis; Malaria in long-term travelers; Malaria prevention
Authors: Jane Cunningham; Jason Horsley; Dipti Patel; Anne Tunbridge; David G Lalloo Journal: Travel Med Infect Dis Date: 2014-01-14 Impact factor: 6.211
Authors: Peter E Nasveld; Michael D Edstein; Mark Reid; Leonard Brennan; Ivor E Harris; Scott J Kitchener; Peter A Leggat; Philip Pickford; Caron Kerr; Colin Ohrt; William Prescott Journal: Antimicrob Agents Chemother Date: 2009-12-07 Impact factor: 5.191
Authors: A P Hopperus Buma; P P van Thiel; H O Lobel; C Ohrt; E J van Ameijden; R L Veltink; D C Tendeloo; T van Gool; M D Green; G D Todd; D E Kyle; P A Kager Journal: J Infect Dis Date: 1996-06 Impact factor: 5.226
Authors: Patricia Schlagenhauf; Alois Tschopp; Richard Johnson; Hans D Nothdurft; Bernhard Beck; Eli Schwartz; Markus Herold; Bjarne Krebs; Olivia Veit; Regina Allwinn; Robert Steffen Journal: BMJ Date: 2003-11-08